Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LZM009 monotherapy in recurrent or metastatic thymic carcinoma (Phase II)
ChiCTR2100045890Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University, Shandong Provincial Institute of Cancer Prevention and Treatment (Shandong Cancer Hospital), Shanghai Chest Hospital
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lipustobart in thymic carcinoma (TC), sponsored by West China Hospital of Sichuan University, Shandong Provincial Institute of Cancer Prevention and Treatment (Shandong Cancer Hospital), Shanghai Chest Hospital. Primary endpoint: Objective Response Rate (ORR). Started Nov 2019; status: recruiting.
02
Drugs
lipustobart
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2100045890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045890.